-
L1023 Anti-Cancer Compound Library: Empowering Target Dis...
2025-09-22
Explore how the L1023 Anti-Cancer Compound Library accelerates drug discovery for clear cell renal cell carcinoma (ccRCC) and other malignancies by enabling high-throughput screening of potent, cell-permeable anti-cancer agents targeting critical pathways such as BRAF kinase, EZH2, and mTOR.
-
eukaryotic translation initiation factor 3
2025-09-19
-
Plerixafor (AMD3100) in Translational Research: Mechanism...
2025-09-19
Explore the multifaceted research applications of Plerixafor (AMD3100), a potent CXCR4 chemokine receptor antagonist, with a focus on its mechanistic role in hematopoietic stem cell and neutrophil mobilization, cancer metastasis inhibition, and emerging directions beyond oncology.
-
Anti-mTOR Rabbit Polyclonal Antibody
2025-09-19
-
WY-14643 (Pirinixic Acid): A Selective PPARα Agonist Shap...
2025-09-18
This article examines WY-14643 (Pirinixic Acid) as a potent and selective PPARα agonist, highlighting its applications in metabolic disorder research and its roles in lipid metabolism regulation and TNF-α mediated inflammation. Recent findings in cancer biology and inflammation are contextualized to inform experimental design and mechanistic studies.
-
GSK963
2025-09-18
-
Cefotetan
2025-09-18
-
GNE-064
2025-09-17
-
Anti-GRP78 BiP Rabbit Polyclonal Antibody
2025-09-17
-
ANP (1-11), rat
2025-09-16
-
BT173
2025-09-16
-
Dienestrol
2025-09-15
-
MARK-IN-1
2025-09-13
-
1-Boc-azetidine-3-yl-methanol
2025-09-13
-
Enniatin B
2025-09-12